A new report from Transparency Market Research highlights readers about the new developments in the global postmenopausal hormone therapy market. The global market for postmenopausal hormone therapy is expected to experience a considerable momentum owing to the rising awareness among people about menopausal symptoms and its treatment. The rising population base of post-menopausal women is another important factor expected to contribute towards the growth of the global postmenopausal hormone therapy market. Postmenopausal hormone therapy comprises replenishment of progestin hormones and body levels of estrogen in women via external consumption of hormones. This therapy is primarily used to minimize symptoms such as hot flashes, vaginal dryness, night sweats, and disturbed sleep.
Request Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13568
The report, titled “Postmenopausal Hormone Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024,” finds that this therapy consist synthetic and natural estrogens. To improve the menopausal treatment, it can also be given in supplement with progesterone. Post-menopausal syndrome is primarily treated with continuous or sequential schedules through numerous doses of progestin, estrogen, or a combination of both. Irrespective of the recent confusion and controversy over the safety of this therapy, the global market has gained steady momentum in the recent past and it is expected to grow in the years to come.
The recent developments in postmenopausal hormone therapy have led to the introduction of advanced and safe therapies. The increasing funding from governments of many nations have also contributed towards the introduction of new therapies, which is another factor boosting the global postmenopausal hormone therapy market. The non-hormonal treatment comparatively has least efficiency to produce required results, which is why the demand for postmenopausal hormone therapies is expected to increase in the years to come.
However, the cost of this therapy is the key factor expected to hamper the growth of the global postmenopausal hormone therapy market. The yearly cost of the postmenopausal hormone therapy is approximately US$10,000, which is slightly on the higher side as compared to the non-hormonal therapy. The post-therapy risks and complications are expected to further challenge the growth of the global market.
Key companies are working on introducing new postmenopausal hormone therapies at affordable prices, which is expected to propel the global market in the long run. The global postmenopausal hormone therapy market is segmented on the basis of region, end user, product, dosage form, therapy, and route of administration. Patches, creams, tablets, suppositories, and injections are some of the products of postmenopausal hormone therapy.
Abbott Laboratories, Bayer Pharma AG, Novo Nordisk A/S, AbbVie, Inc., and Hisamitsu Pharmaceutical Co., Inc. are some of the key companies operating in the global postmenopausal hormone therapy market.
